Ascendis Pharma bags YORVIPATH FDA approval for adult hypoparathyroidism
In a landmark decision, the U.S. Food and Drug Administration (FDA) has granted approval to Ascendis Pharma A/S’s YORVIPATH (palopegteriparatide), making it the first and ... Read More
FDA accepts Ascendis Pharma’s TransCon hGH BLA for pediatric GHD
Ascendis Pharma, a Danish biopharma company, said that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for TransCon hGH ... Read More